Statins are among the most widely prescribed medications in the world, credited with preventing heart attacks and strokes in millions of people, yet a stubborn debate surrounds how often they cause the muscle aches that lead many patients to quit them. Observational studies have reported that as many as one in five older patients experience muscle-related complaints while taking the drugs, a figure frequently cited to explain why so many people abandon a treatment that lowers cardiovascular risk. But rigorous clinical trials tell a more complicated story, one in which most of those symptoms turn out not to be caused by the medication itself.
What statin-associated muscle symptoms actually are
The complaints that patients describe range from aching and soreness to weakness and cramps, a cluster clinicians label statin-associated muscle symptoms. Estimates of how common they are vary widely depending on how the data are gathered. Guidance from the National Lipid Association’s clinical review of statin-associated muscle symptoms places the reported prevalence in the general population at roughly 10 percent, with a range spanning about 5 to 25 percent, which is where the widely repeated “up to one in five” framing originates. Crucially, that figure captures everyone who reports muscle symptoms regardless of the true cause. When the same review isolates symptoms that can be attributed to the drug’s pharmacology, the estimate falls dramatically, to somewhere on the order of 1 to 2 percent.
The nocebo effect and what trials revealed
The gap between reported symptoms and drug-caused symptoms points to the nocebo effect, in which the expectation of a side effect produces the sensation of that side effect even without an active drug. The clearest demonstration came from a trial that gave participants months of statin pills, months of identical-looking placebo pills, and months of no pills at all, in a randomized order. As summarized by the British Heart Foundation’s account of the SAMSON trial, roughly 90 percent of the symptom burden that patients experienced on the statin was also present when they took the dummy pill, indicating that the overwhelming majority of complaints were not caused by the medication. Notably, once patients saw that finding for themselves, about half chose to resume statin therapy, underscoring how much the perception of harm drives discontinuation.
Why older patients weigh the balance differently
Age complicates the picture in both directions. Older adults are more likely to be taking statins in the first place, because cardiovascular risk climbs with age, and they are also more likely to be managing other conditions and medications that can independently cause muscle aches, making it harder to pin symptoms on any single drug. At the same time, older patients often stand to gain the most from the protection statins provide against heart attacks and strokes. Public-health guidance on managing cholesterol, including material from the National Heart, Lung, and Blood Institute on blood cholesterol, frames statins as a cornerstone of prevention for people at elevated risk, precisely the group in which age concentrates that risk. The clinical challenge is ensuring that a treatable, often nocebo-driven symptom does not cause a patient to forfeit a proven benefit.
How clinicians manage genuine intolerance
None of this means muscle symptoms are imaginary or that true statin intolerance does not exist; a small fraction of patients do experience real, drug-related muscle problems, and in rare cases statins can cause a serious condition involving muscle breakdown. The standard approach when a patient reports symptoms is not simply to stop the drug permanently but to investigate methodically: pausing the medication to see whether symptoms resolve, rechecking after restarting, adjusting the dose, or switching to a different statin, since tolerance can vary between formulations. Federal and clinical resources on cholesterol treatment, including the cardiovascular guidance maintained by the Centers for Disease Control and Prevention on cholesterol, emphasize shared decision-making so that patients understand both the real risks and the substantial benefits before abandoning therapy.
The stakes of stopping
The practical concern behind the debate is that a large share of people prescribed statins stop taking them within a couple of years, frequently citing muscle symptoms, and that discontinuation carries its own risk in the form of unprotected cardiovascular disease. Coverage of ongoing research on the topic, including reporting aggregated by outlets such as ScienceDaily, has helped publicize the trial evidence on the nocebo effect, but the message often struggles to compete with the vivid personal experience of an aching muscle. For older patients weighing whether to continue, the evidence suggests a middle path: taking reported symptoms seriously, investigating them systematically with a clinician, and recognizing that the sensation of a side effect is not proof that the drug caused it, before giving up a medication with a well-documented capacity to prevent heart attacks and strokes.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Card skimmers hidden on gas pumps and ATMs are draining accounts, and here’s the tell
- The FBI says hackers are hijacking outdated home routers, and it named the models to check
- Older Teslas are wearing out in ways early owners never saw coming
- A common childhood virus is now tied to multiple sclerosis years later
